[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:kidney-medullary-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":29,"states":30},"Kidney Medullary Carcinoma",3,2,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06444880","Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies",[12],"Phase 2","RECRUITING","2026-08-03T03:45:11.273644Z","2026-05-05T02:43:27.586903Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06161532","Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder\u002FUrinary Tract Cancer, Renal Medullary Carcinoma and Penile C...",[12],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:28.172497Z",{"nct_id":23,"title":24,"phases":25,"status":26,"updated_at":27,"content_modified":28},"NCT07438626","Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:33.772093Z","2026-05-05T02:43:27.396122Z",[],[]]